



University of Pittsburgh

Schools of the Health Sciences Media Relations

Contact: Anita Srikameswaran
Phone: 412-578-9193
E-mail: SrikamAV@upmc.edu

Contact: Wendy Zellner
Phone: 412-586-9777
E-mail: ZellnerWL@upmc.edu

FOR IMMEDIATE RELEASE

University of Pittsburgh and UPMC Enter Partnership with Johnson & Johnson Corporate Office of Science and Technology to Jointly Fund Research

PITTSBURGH, March 1 - The [University of Pittsburgh](#) and [UPMC](#) have entered into a partnership with [Johnson & Johnson Corporate Office of Science and Technology](#) (COSAT) to support translational research, which transforms lab findings into usable products and services, by jointly allocating research monies to university faculty from a mutually established fund.

COSAT has a long history of supporting the development of technologies through collaboration with academic institutions, and Pitt holds a strong record of moving basic scientific research from the lab to the patient's bedside. The new agreement is designed to improve the speed of development of early stage Pitt technologies that hold the greatest potential to benefit patients and improve services delivered by the health care system.

Pitt will lead a committee including representatives from COSAT and UPMC to identify projects of promise that could benefit from funding support. As with other research efforts, intellectual property or technologies developed at Pitt through this program will be owned by the university and made available through licensing agreements to industry collaborators through well-established procedures.

[Arthur S. Levine, M.D.](#), Pitt's senior vice chancellor for the health sciences and dean, School of Medicine, noted that "The university has tremendous capabilities in all aspects of biomedical research. This new partnership with COSAT will foster the continued development of high-caliber work with great scientific and therapeutic potential."

The University of Pittsburgh and UPMC recently formed a pharmaceutical collaboration committee to address how best to work with the pharmaceutical and biotech industries, including the co-mingled COSAT fund. The committee is led by D. Lansing Taylor, Ph.D., director of the University of Pittsburgh Drug Discovery Institute and Allegheny Foundation Professor of Computational and Systems Biology, and composed of faculty from the Dietrich School of Arts and Sciences, and the Schools of Medicine and Pharmacy, as well as staff from the university's Office of Technology Management and UPMC.

#

About the University of Pittsburgh School of Medicine

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1997.

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of

Medicine is the academic partner of [UPMC](#), which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see www.medschool.pitt.edu.

<http://www.upmc.com/mediarelations>